The multiple sclerosis (MS) clinical course and relapses frequency before progression vary widely.
Objective:
To investigate the influence of age on the MS phenotype.
Methods:
Among 751 primary progressive (PP = 217) and secondary progressive (SP = 534) MS patients from the London Ontario database, we assessed the relationship of age on the relapse frequency and on the progressive phase evolution, and the impact of relapses on the age at onset of progression.
Results:
Age at onset did not influence the early attacks frequency, but patients younger at onset had larger number of total attacks before progression (age = 27.4, 31.0 and 32.8 mean years; ⩾4, 2–3 and 1 relapses, respectively) and longer latency to SP. Although frequent early relapses predicted younger age at SP onset, patients with no attacks (primary progressive multiple sclerosis (PPMS)), or 1, 2–3 and ⩾4 relapses during the relapsing-remitting phase started progressing at similar age (38.6, 41.3, 41.4 and 39.2 mean years, respectively). The age at onset of progressive phase did not affect its evolution.
Conclusions:
Age strongly influences the phenotype before progression. Relapsing-remitting patients younger at onset are more likely to display a predominantly inflammatory course, yet relapses number does not affect the age at onset of progression.
LublinFDReingoldSCCohenJA. Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology2014; 83: 278–286.
2.
ScoldingNBarnesDCaderS. Association of British Neurologists: Revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol2015; 15: 273–279.
ReynoldsRRoncaroliFNicholasR. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol2011; 122: 155–170.
5.
ScalfariANeuhausADegenhardtA. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain2010; 133(Pt 7): 1914–1929.
6.
LerayEYaouanqJLe PageE. Evidence for a two-stage disability progression in multiple sclerosis. Brain2010; 133(Pt 7): 1900–1913.
7.
ConfavreuxCVukusicSAdeleineP.Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain2003; 126: 770–782.
8.
TremlettHYousefiMDevonshireV. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology2009; 73: 1616–1623.
9.
TrappBDPetersonJRansohoffRM. Axonal transection in the lesions of multiple sclerosis. N Engl J Med1998; 338: 278–285.
10.
TutuncuMTangJZeidNA. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler2013; 19: 188–198.
11.
ScalfariANeuhausADaumerM. Age and disability accumulation in multiple sclerosis. Neurology2011; 77: 1246–1252.
12.
ConfavreuxCVukusicS.Natural history of multiple sclerosis: A unifying concept. Brain2006; 129: 606–616.
13.
KochMMostertJHeersemaD. Progression in multiple sclerosis: Further evidence of an age dependent process. J Neurol Sci2007; 255: 35–41.
14.
KremenchutzkyMRiceGPBaskervilleJ. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain2006; 129: 584–594.
15.
KremenchutzkyMCottrellDRiceG. The natural history of multiple sclerosis: A geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: A re-evaluation. Brain1999; 122: 1941–1950.
16.
ScalfariANeuhausADaumerM. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol2013; 70: 214–222.
17.
CottrellDAKremenchutzkyMRiceGP. The natural history of multiple sclerosis: A geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain1999; 122: 625–639.
18.
KurtzkeJF.A new scale for evaluating disability in multiple sclerosis. Neurology1955; 5: 580–583.
19.
DebouverieMPittion-VouyovitchSLouisS. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol2008; 15: 916–921.
20.
TremlettHYinshanZDevonshireV.Natural history of secondary-progressive multiple sclerosis. Mult Scler2008; 14: 314–324.
21.
ErikssonMAndersenORunmarkerB.Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler2003; 9: 260–274.
22.
MowryEMPesicMGrimesB. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology2009; 72: 602–608.
23.
TremlettHZhaoYJosephJ. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatr2008; 79: 1368–1374.
24.
KalincikTVivekVJokubaitisV. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain2013; 136: 3609–3617.
25.
TortorellaCBellacosaAPaolicelliD. Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. J Neurol Sci2005; 239: 95–99.
26.
FrischerJMBramowSDal-BiancoA. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain2009; 132: 1175–1189.
27.
KhademiMDringAMGilthorpeJD. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: A reflection by cerebrospinal fluid biomarkers. PLoS ONE2013; 8(5): e63172.
28.
ScalfariANeuhausADaumerM. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatr2014; 85: 67–75.
29.
KalincikTBuzzardKJokubaitisV. Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler2014; 20: 1511–1522.
30.
KantarciOHLebrunCSivaA. Primary progressive MS evolving from radiologically isolated syndrome. Ann Neurol. Epub ahead of print 24November2015. DOI: 10.1002/ana.24564.
31.
ConfavreuxCVukusicS.Age at disability milestones in multiple sclerosis. Brain2006; 129: 595–605.
32.
SignoriASchiavettiIGalloF. Subgroups of multiple sclerosis patients with larger treatment benefits: A meta-analysis of randomized trials. Eur J Neurol2015; 22: 960–966.
33.
MatellHLyckeJSvenningssonA. Age-dependent effects on the treatment response of natalizumab in MS patients. Mult Scler2015; 21: 48–56.
34.
HutchinsonMKapposLCalabresiPA. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol2009; 256: 405–415.
35.
SaccardiRKozakTBocelli-TyndallC. Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler2006; 12: 814–823.
